Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 19/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6701344 | 0.91 | PPARG (0.57) | PPARGTP53SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6715707 | 0.90 | PPARG (0.56) | PPARGTP53SMN1; SMN2 | |
| SCHEMBL6699632 | 0.88 | PPARG (0.54) | PPARGTP53SMN1; SMN2 | |
| SCHEMBL14198125 | 0.87 | PPARG (0.53) | PPARGTP53SMN1; SMN2 | |
| SCHEMBL6697787 | 0.86 | PPARG (0.54) | PPARGTP53SMN1; SMN2 | |
| SCHEMBL6701593 | 0.85 | PPARG (0.54) | PPARGTP53SMN1; SMN2 | |
| SCHEMBL6703323 | 0.85 | PPARG (0.57) | PPARGTP53SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7076829 | 0.84 | PPARG (0.56) | PPARGTP53SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6723924 | 0.84 | PPARG (0.56) | PPARGTP53SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6723941 | 0.84 | PPARG (0.56) | PPARGTP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1915994-B1 | CYCLIC AMINE DERIVATIVES IN COMBINATION WITH PPAR REGULATORS | DAIICHI SANKYO CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-01 | — | — | US | disclosed |
| US-6596751-B2 | An insulin resistance improving agent, hypoglycemic agent, immunoregulatory agent, aldose reductase inhibitor, 5-lipoxygenase inhibitor, peroxidized lipid production suppressor, PPAR. activator, leukotriene antagonist, adipose | SANKYO COMPANY LIMITED (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
| EP-1167357-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | PPARG 152/4885TP53 3629/4885SMN1; SMN2 2259/4885 |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | PPARG 152/4885TP53 3629/4885SMN1; SMN2 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.